Key facts
- It has raised $3.0M; the latest was Later Stage VC ($3.0M) in Jan 2026.
- Notable investors include Google Accelerator, Myosotis Investments, Oncode Oncology Bridge Fund.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Cyclomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cyclomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cyclomics
Operator of a biotechnology company intended to specialize in advanced molecular diagnostics and DNA sequencing. The company utilizes cutting-edge technologies like Nanopore sequencing and proprietary molecular assays to focus on detecting and monitoring cancer through precise analysis of circulating tumor DNA from liquid biopsies, enabling researchers in non-invasive cancer detection, providing critical insights into tumor dynamics and treatment efficacy.
- Sector
- Healthcare
- HQ
- Amsterdam, Netherlands
- Founded
- 2017
- Employees
- 10
- Website
- cyclomics.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Cyclomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyclomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyclomics in its N-PORT filings yet. We sweep new filings monthly.